You are here

Clinical Trials: Cord Blood

Comment

Discuss
Conditions:   Myelodysplastic Syndrome (MDS);   Severe Aplastic Anemia (SAA)
Interventions:   Other: Umbilical Cord Blood;   Other: Haploidentical Stem Cells;   Device: Miltenvi CliniMACs CD34 Reagent System
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified December 6, 2016
Condition:   Chronic Granulomatous Disease
Interventions:   Drug: Busulfan;   Biological: Alemtuzumab;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Cyclosporine;   Procedure: Stem Cell Infusion
Sponsors:   Baylor College of Medicine;   Texas Children's Hospital
Active, not recruiting - verified July 2017
Condition:   Lymphoma
Interventions:   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: gemcitabine hydrochloride;   Drug: ifosfamide;   Drug: mechlorethamine hydrochloride;   Drug: melphalan;   Drug: methotrexate;   Drug: mycophenolate mofetil;   Drug: prednisone;   Drug: procarbazine hydrochloride;   Drug: vincristine sulfate;   Drug: vinorelbine tartrate;   Procedure: allogeneic bone marrow transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
Sponsors:   Memorial Sloan Kettering Cancer Center;   National Cancer Institute (NCI)
Active, not recruiting - verified May 2017
Conditions:   Leukemia;   Lymphoma;   Myelodysplastic Syndromes
Interventions:   Biological: filgrastim;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: mycophenolate mofetil;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
Active, not recruiting - verified August 2017
Condition:   Inherited Immune Deficiencies
Interventions:   Drug: Fludarabine;   Drug: Total Body Irradiation, Busulfan, Campath-1H, or h-ATG, Fludarabine;   Drug: Sirolimus or equivalent based on response;   Drug: Granulocyte Colony Stimulating Factor (G-CSF);   Other: hematopoietic progenitor cells
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified December 1, 2016
Conditions:   Sickle Cell Disease;   Beta Thalassemia
Interventions:   Drug: Busulfan;   Drug: Fludarabine;   Drug: Alemtuzumab;   Procedure: Allogeneic stem cell transplant
Sponsor:   Columbia University
Recruiting - verified July 2017
Conditions:   Leukemia;   Myelodysplastic Syndromes;   Childhood Acute Myeloid Leukemia in Remission;   Recurrent Childhood Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Previously Treated Myelodysplastic Syndrome;   Secondary Myelodysplastic Syndrome;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Anemia With Excess Blasts;   Refractory Anemia;   De Novo Myelodysplastic Syndrome;   Childhood Myelodysplastic Syndrome
Interventions:   Biological: filgrastim;   Drug: busulfan;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation
Sponsor:   Masonic Cancer Center, University of Minnesota
Recruiting - verified June 2017
Conditions:   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
Interventions:   Biological: anti-thymocyte globulin;   Biological: sargramostim;   Drug: busulfan;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: umbilical cord blood transplantation
Sponsors:   University of California, San Francisco;   National Cancer Institute (NCI)
Completed - verified September 2017
Conditions:   Leukemia, Myeloid, Chronic;   AML;   Leukemia, Lymphocytic, Acute;   MDS;   Leukemia, Lymphocytic, Chronic;   JMML;   Hodgkin's Disease;   Non-hodgkin's Lymphoma;   Multiple Myeloma
Interventions:   Procedure: Stem Cell Transplant;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Drug: Busulfan
Sponsor:   Masonic Cancer Center, University of Minnesota
Recruiting - verified July 2017
Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions:   Biological: anti-thymocyte globulin;   Biological: graft-versus-tumor induction therapy;   Biological: sargramostim;   Biological: therapeutic allogeneic lymphocytes;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: methylprednisolone;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: allogeneic bone marrow transplantation;   Procedure: peripheral blood stem cell transplantation;   Procedure: umbilical cord blood transplantation
Sponsor:   Roswell Park Cancer Institute
Active, not recruiting - verified March 2017
Condition:   Severe Combined Immunodeficiency Syndrome
Intervention:   Drug: CD34+ cells transduced with ADA retrovir
Sponsor:   National Human Genome Research Institute (NHGRI)
Completed - verified September 17, 2014
Conditions:   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
Interventions:   Biological: anti-thymocyte globulin;   Biological: filgrastim;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: methylprednisolone;   Procedure: bone marrow ablation with stem cell support;   Procedure: umbilical cord blood transplantation;   Radiation: radiation therapy
Sponsor:   Roswell Park Cancer Institute
Active, not recruiting - verified March 2017

Pages